---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-034216"
form_type: "8-K"
ticker: "CELU"
cik: "0001752828"
company_name: "Celularity Inc"
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:12:38.864500+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Celularity appoints Richard J. Berman to Board; reduces board from 7 to 6

## Summary
- Richard J. Berman appointed as Class II director, effective Aug 27, 2024, to fill vacancy left by Robin L. Smith.
- Berman received an option to purchase 118,111 shares at $3.01/share, vesting in three equal annual installments.
- Board reduced from seven to six directors following Marc Mazur's departure; Class III reduced from two to one.
- Berman brings over 40 years of VC and M&A experience; served on boards of six companies over $1B market value.
- He was appointed to the Audit Committee; qualifies as independent under Nasdaq rules.

## SEC filing metadata
- accession: 0001493152-24-034216
- form_type: 8-K
- ticker: CELU
- cik: 0001752828
- company_name: Celularity Inc
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1752828/000149315224034216/0001493152-24-034216-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1752828/000149315224034216/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-034216
- JSON: https://secwatch.observer/filing/0001493152-24-034216.json
- Plain text: https://secwatch.observer/filing/0001493152-24-034216.txt

## Key facts
- Executive change
  Richard J. Berman was appointed as Director at Celularity Inc.
  - Action: appointed
  - Role: Director
  source text: On August 27, 2024, the board of directors, or the Board, of Celularity Inc., or Celularity, appointed Richard J. Berman, as a Class II director to fill the vacancy left by the resignation of Robin L. Smith, M.D.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1752828/000149315224034216/0001493152-24-034216-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.